Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + Pemetrexed
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Trial Timeline
Mar 27, 2014 → May 27, 2022
NCT ID
NCT02041533About Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + Pemetrexed
Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + Pemetrexed is a phase 3 stage product being developed by Ono Pharmaceutical for Stage IV or Recurrent Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02041533. Target conditions include Stage IV or Recurrent Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Stage IV or Recurrent Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02041533 | Phase 3 | Completed |
Competing Products
20 competing products in Stage IV or Recurrent Non-Small Cell Lung Cancer